DTIL stock took a big bounce off what could be a bottom in the stock after the company announced a new in-house manufacturing facility in the U.S.

Precision BioSciences opened its Manufacturing Center for Advanced Therapeutics, the first in-house current Good Manufacturing Process compliant manufacturing facility in the U.S. dedicated to genome-edited, off-the-shelf chimeric antigen receptor T cell therapy products. This is part of a larger investment by the company in its cancer immunotherapy platform and facilities expansions in North Carolina in 2019. Currently, the new facility is unde...